Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > ORGANIZATION
ORGANIZATION
- AMDJ to Draw Up Voluntary Rules for Managing Big Data in Field of Healthcare
October 14, 2015
- ACCJ Applauds Conclusion of TPP Talks
October 8, 2015
- EFPIA Vice President Has High Hopes for Japan’s Innovation
October 7, 2015
- EFPIA Director General Welcomes Broad Deal Reached on TPP
October 7, 2015
- JPMA President Congratulates Nobel Laureate Omura
October 7, 2015
- Drug Pricing Tomorrow: Full Interview with JMA Vice President Nakagawa
October 5, 2015
- New 3 Price-Band Rule Will Boost Predictability, Foster Healthy Competition: JGA Officials
October 2, 2015
- “Humanitarian Trials” Not Welcomed but Well-Designed: JPMA Regulatory Chief
September 30, 2015
- JPWA Asks LDP Bigwigs to Simplify Market Price Survey for Tax Hike If Conducted at All
September 30, 2015
- Drug Pricing Tomorrow: JMA’s Nakagawa Says Price Maintenance Premium Should Continue as Trial Measure
September 29, 2015
- April-June Generic Share at 54.4%: JGA
September 28, 2015
- Kenporen Proposal Prods Health Coverage Removal for “1st-Generation Poultices”
September 25, 2015
- JPMA Reprimands Pfizer over Failure to Report ADRs
September 18, 2015
- JPMA Helping Member Firms Expand into Emerging Asian Markets: Int’l Affairs Chief
September 17, 2015
- JPMA Policy Research Unit Sets Up Study Group on Big Data
September 10, 2015
- Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 2
September 8, 2015
- JPMA Chief Lauds MHLW’s Comprehensive Strategy, Says It Will Support Industry as a Whole
September 7, 2015
- JPMA to Start Educational Program for Biopharmaceutical Manufacturing Next Spring: Biopharmaceutical Chief
September 4, 2015
- Ryukaikon’s New Proposal “Will Greatly Promote the Improvement of Distribution”: JPWA President
September 2, 2015
- Cost-Effective Assessment Must Not Delay Patient Access: PhRMA’s HTA Chief
September 1, 2015
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…